Research Analysts Offer Predictions for ADIL Q3 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Equities researchers at Litchfield Hills Research dropped their Q3 2025 EPS estimates for shares of Adial Pharmaceuticals in a note issued to investors on Wednesday, September 24th. Litchfield Hills Research analyst T. O’neill now forecasts that the company will earn ($0.09) per share for the quarter, down from their prior forecast of ($0.08). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.53) EPS and FY2026 earnings at ($0.38) EPS.

Several other analysts also recently weighed in on the company. Wall Street Zen upgraded Adial Pharmaceuticals to a “sell” rating in a research note on Saturday, July 26th. Zacks Research cut Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $8.00.

Adial Pharmaceuticals Stock Performance

Shares of NASDAQ ADIL opened at $0.33 on Friday. The company has a 50 day simple moving average of $0.40 and a two-hundred day simple moving average of $0.52. Adial Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $1.30. The company has a market capitalization of $7.31 million, a price-to-earnings ratio of -0.32 and a beta of 1.08.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04.

Hedge Funds Weigh In On Adial Pharmaceuticals

A hedge fund recently raised its stake in Adial Pharmaceuticals stock. Citadel Advisors LLC lifted its holdings in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 63.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,508 shares of the company’s stock after buying an additional 21,238 shares during the period. Citadel Advisors LLC owned approximately 0.85% of Adial Pharmaceuticals worth $55,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.